Skip to content

Antimicrobial Stewardship for Enterobacterales Bacteremia Management

A Cluster-randomized Controlled Pragmatic Trial to Evaluate Antimicrobial Stewardship Strategies for Short-course and Oral-switch Antibiotic Therapy for Bloodstream Infections Due to Enterobacterales

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06257147
Enrollment
420
Registered
2024-02-13
Start date
2024-05-01
Completion date
2026-11-30
Last updated
2024-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infections

Brief summary

We hypothesize that a multifaceted antibiotic stewardship intervention incorporating physician education, prospective chart review with antibiotic recommendation, and provision of follow-up by a multidisciplinary antibiotic stewardship team, is more effective than physician education and reminders alone in improving physicians' prescription of short-course and oral-switch antibiotic therapy for patients with bloodstream infections due to Enterobacterales (BSI-E). This study is to: 1. determine the effectiveness of a multifaceted antibiotic stewardship intervention in improving physicians' prescription of short-course antibiotic therapy for BSI-E 2. determine the effectiveness of a multifaceted antibiotic stewardship intervention in improving physicians' de-escalation to oral antibiotic therapy for BSI-E

Detailed description

Antimicrobial resistance is a major global threat, causing 5 million deaths globally in 2019. One of the crucial strategies to control the emergence and spread of multidrug-resistant organisms (MDRO) is to minimize unnecessary antibiotics exposure. Shorter duration of antibiotic therapy and oral-switch therapy for bloodstream infection due to Enterobacterales (BSI-E) had demonstrated similar treatment success and clinical outcomes as compared with longer courses in randomized controlled trials. Despite the release of such data, clinicians may be reluctant to shortern duration of therapy for BSI-E and adopt oral-switch approach. This study aims to determine the optimal approach to aid clinicians in adopting evidence-based practice in a clinical setting. This study is a pragmatic cluster-randomized controlled trial in the medical wards of an acute hospital. A cluster, as the unit of randomization, is a medical ward. Medical wards will be randomized to three groups: (1) physician education only; (2) physician education and paper reminder; (3) multifaceted antibiotic stewardship intervention. The prescription of antibiotic therapy by treating physicians and outcomes of patients with BSI-E will be studied. Patients' antibiotics regimen and clinical outcomes in the three groups will be compared.

Interventions

BEHAVIORALmultifaceted antibiotic stewardship intervention

Group 3 wards will receive a multifaceted antibiotic stewardship intervention. Physician education will be provided as in Group 1. All consecutive patients fulfilling inclusion and exclusion criteria for study eligibility will be assessed by an Antibiotic Stewardship team. A trained nurse will first assess the patients for clinical and host criteria to determine eligibility for short-course antibiotic therapy. The antibiotic susceptibility test results and the prescribed antibiotics treatment will be reviewed. An Infectious Diseases physician will subsequently make written recommendations for the duration and choice of antibiotic therapy, and provide an appointment within 2 weeks after hospital discharge to review patients' clinical condition when indicated.

Sponsors

Chinese University of Hong Kong
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* aged ≥18 years; * hospitalization in one of the medical wards of the hospital; and * isolation of Enterobacterales in at least one blood culture bottle, where Enterobacterales include Escherichia coli, Klebsiella, Proteus, Enterobacter, Serratia, Citrobacter, Providencia and Morganella species.

Exclusion criteria

* concomitant isolation of pathogens other than Enterobacterales in blood or other relevant clinical specimens; * infections requiring prolonged courses of antibiotics, such as intra-abdominal abscess, central nervous system infection, endocarditis, lung abscess or empyema, osteomyelitis, and prostatitis; * focus of infection not controlled; * nosocomial infection with onset within 7 days; or * Presence of neutropenia, allogenic stem cell transplant within one year, use of high-dose steroid (\>40mg prednisolone or equivalent for \> 2 weeks), or * died before day 7 will be excluded from the analysis, or * already on more than 7 days of antibiotics for BSI-E at the time of screening.

Design outcomes

Primary

MeasureTime frameDescription
Percentage of patients receiving 7 days effective antibiotic therapy for the treatment of BSI-E7 daysproportion of patients receiving 7 days of effective antibiotic therapy for the treatment of BSI-E

Secondary

MeasureTime frameDescription
proportion of patients with susceptible oral antibiotics completed the course with an oral antibioticduring hopsitalizationproportion of patients with susceptible oral antibiotics completed the course with an oral antibiotic
30-day all-cause mortality30 day since hospital admission30-day all-cause mortality
clinical failurewithin 90 days since hopsitalizationclinical failure , defined as relapse of BSI-E due to the same Enterobacterales, local suppurative complications or distant complications due to the same pathogen within 90 days
length of stay in hospitalfrom the admission up to the dischargelength of stay in hospital
re-admission to hospital within 90 dayswithin 90 days since dischargere-admission to hospital within 90 days

Countries

Hong Kong

Contacts

Primary ContactCatherine Cheung
catherinecheung@cuhk.edu.hk35053376

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026